Katharine Yen

17.6k citations

38 papers · 5.9k indexed · 2 hit papers · h-index 22

Molecular Biology top 2%
Cancer Research top 0.5%
Genetics top 0.2%
Hematology top 0.5%
Oncology top 5%

Co-authors: Lenny Dang Shinsan M. Su Valeria R. Fantin Shengfang Jin Stefan Größ Craig B. Thompson Patrick S. Ward Matthew G. Vander Heiden
Topics: Acute Myeloid Leukemia Research (19 papers)Cancer, Hypoxia, and Metabolism (16 papers)Glioma Diagnosis and Treatment (13 papers)
Cited by: Genetics Cancer Research Hematology
Journals: Nature Nature Medicine Journal of Clinical Oncology
Partner nations: United States France Canada

In The Last Decade

Katharine Yen

36 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

2009 3.1k citations Lenny Dang, David W. White et al. Nature profile →
IDH mutations in cancer and progress toward development of targeted therapeutics

2016 363 citations Lenny Dang, Katharine Yen et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Katharine Yen

Since Specialization

Citations

This map shows the geographic impact of Katharine Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katharine Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katharine Yen more than expected).

Fields of papers citing papers by Katharine Yen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katharine Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katharine Yen. The network helps show where Katharine Yen may publish in the future.

Co-authorship network of co-authors of Katharine Yen

This figure shows the co-authorship network connecting the top 25 collaborators of Katharine Yen. A scholar is included among the top collaborators of Katharine Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katharine Yen. Katharine Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 903: AURIGIN: A comprehensive single-cell OMICs atlas of human development and an AI/ML framework to classify and identify the drivers of tumor plasticity and altered cellular state 2024 ·Cancer Research ·(unknown),Henry S. Wilson,Kimberly Straley,Maulasri Bhatta,Sambad Sharma,(unknown),(unknown),Betty Chan,Andrew J. McRiner,Mark Bittinger,(unknown),Katharine Yen,Thomas G. Graeber,David S. Millan	0
2	AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model 2024 ·Blood ·(unknown),(unknown),(unknown),Maulasri Bhatta,(unknown),(unknown),(unknown),Betty Chan,(unknown),Christophe Marzac,Jean‐Baptiste Micol,(unknown),Stéphane de Botton,Katharine Yen,David S. Millan,Iléana Antony‐Debré,Kimberly Straley	1
3	Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation 2023 ·Nature Medicine ·Birgit Geoerger,Manuel Schiff,Virginie Penard‐Lacronique,Niklas Darín,(unknown),(unknown),Antonin Lamazière,(unknown),Clément Pontoizeau,Pablo Berlanga,Stéphane Ducassou,Katharine Yen,Michael Su,David P. Schenkein,Chris Ottolenghi,Stéphane de Botton	5
4	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia 2017 ·Cancer Discovery ·Alan H. Shih,Cem Meydan,Kaitlyn Shank,Francine E. Garrett-Bakelman,Patrick S. Ward,Andrew M. Intlekofer,Abbas Nazir,Eytan M. Stein,Kristina M. Knapp,Jacob L. Glass,Jeremy Travins,(unknown),Camelia Gliser,Christopher E. Mason,Katharine Yen,Craig B. Thompson,Ari Melnick,Ross L. Levine	71
5	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response 2017 ·Blood ·Michael Amatangelo,Lynn Quek,Alan H. Shih,Eytan M. Stein,Mikhail Roshal,Muriel D. David,Benoît Marteyn,Noushin Farnoud,Stéphane de Botton,Olivier Bernard,Bin Wu,Katharine Yen,Martin S. Tallman,Elli Papaemmanuil,Virginie Penard‐Lacronique,Anjan Thakurta,Paresh Vyas,Ross L. Levine	249
6	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML 2017 ·Leukemia ·Lev M. Kats,Stephin J. Vervoort,Rachel M. Cole,(unknown),Gareth P. Gregory,Eva Vidacs,Jason Li,Raj Nagaraja,Katharine Yen,Ricky W. Johnstone	23
7	IDH mutations in cancer and progress toward development of targeted therapeuticsbreakdown → 2016 ·Annals of Oncology ·Lenny Dang,Katharine Yen,Eyal C. Attar	363
8	Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer 2016 ·Clinical Cancer Research ·Owen Clark,Katharine Yen,Ingo K. Mellinghoff	147
9	Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance 2014 ·Cell stem cell ·Lev M. Kats,Markus Reschke,Riccardo Taulli,Olga Pozdnyakova,Kerri Burgess,Parul Bhargava,Kimberly Straley,Rahul Karnik,Alexander Meissner,Donald Small,Shinsan M. Su,Katharine Yen,Jiangwen Zhang,Pier Paolo Pandolfi	146
10	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo 2014 ·Blood ·Erica Hansen,Cyril Quivoron,(unknown),René M. Lemieux,Janeta Popovici-Müller,Hossein Sadrzadeh,Amir T. Fathi,Camelia Gliser,Muriel D. David,Véronique Saada,Jean‐Baptiste Micol,Olivier Bernard,Marion Dorsch,Hua Yang,Michael Su,Sam Agresta,Stéphane de Botton,Virginie Penard‐Lacronique,Katharine Yen	40
11	AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies 2014 ·Blood ·Eytan M. Stein,Jessica K. Altman,Robert H. Collins,Daniel J. DeAngelo,Amir T. Fathi,Ian W. Flinn,Arthur E. Frankel,Ross L. Levine,Bruno C. Medeiros,Manish R. Patel,Daniel A. Pollyea,Gail J. Roboz,Richard M. Stone,Ronan Swords,Martin S. Tallman,Sam Agresta,Bin Fan,Hua Yang,Katharine Yen,Stéphane de Botton	68
12	Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate 2014 ·The Oncologist ·Amir T. Fathi,Hossein Sadrzadeh,Amy Comander,Michaela J. Higgins,Aditya Bardia,Ashley Perry,Meghan Burke,(unknown),(unknown),Kimberly Straley,Katharine Yen,Sam Agresta,Hyeryun Kim,David P. Schenkein,Darrell R. Borger	59
13	IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition 2014 ·Blood ·Andrew Kernytsky,Fang Wang,Erica Hansen,Stefanie S. Schalm,Kimberly Straley,Camelia Gliser,Hua Yang,Jeremy Travins,Stuart Murray,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Wei Liu,Katharine Yen	128
14	IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model 2013 ·Blood ·Katharine Yen,René M. Lemieux,Janeta Popovici-Müller,Yue Chen,Hua Yang,(unknown),Sung Choe,Marion Dorsch,Samuel Agresta,David P. Schenkein,Scott A. Biller,Michael Su,Fang Wang	13
15	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop 2013 ·Neuro-Oncology ·Jason T. Huse,(unknown),Kenneth Aldape,Mitchel S. Berger,Chetan Bettegowda,Daniel J. Brat,Daniel P. Cahill,Timothy F. Cloughesy,Daphne A. Haas‐Kogan,Marco A. Marra,C. Ryan Miller,Sarah J. Nelson,Sofie R. Salama,Riccardo Soffietti,Patrick Y. Wen,Stephen Yip,Katharine Yen,J Costello,Susan M. Chang	23
16	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo 2012 ·ACS Medicinal Chemistry Letters ·Janeta Popovici-Müller,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Shunqi Yan,Fang Zhao,Stefan Größ,Lenny Dang,Katharine Yen,Hua Yang,Kimberly Straley,Shengfang Jin,Kaiko Kunii,Valeria R. Fantin,Shunan Zhang,(unknown),(unknown),Scott A. Biller,Shinsan M. Su	160
17	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function 2012 ·Genes & Development ·Masato Sasaki,Christiane B. Knobbe‐Thomsen,Momoe Itsumi,Andrew Elia,Isaac S. Harris,Iok In Christine Chio,Rob A. Cairns,Susan McCracken,Andrew Wakeham,Jillian Haight,(unknown),Bryan E. Snow,Takeshi Ueda,Satoshi Inoue,Kazuo Yamamoto,Myunggon Ko,Anjana Rao,Katharine Yen,Shinsan M. Su,Tak W. Mak	224
18	Cancer-associated IDH mutations: biomarker and therapeutic opportunities 2010 ·Oncogene ·Katharine Yen,(unknown),Shinsan M. Su,Valeria R. Fantin	227
19	Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate 2010 ·Cancer Research ·Valeria R. Fantin,Lenny Dang,David W. White,Stefan Größ,Mark Bittinger,Edward M. Driggers,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin M. Marks,Katharine Yen,Patrick S. Ward,Robert M. Prins,Linda M. Liau,Bryson D. Bennett,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Shinsan M. Su	4
20	Cancer-associated IDH1 mutations produce 2-hydroxyglutaratebreakdown → 2009 ·Nature ·Lenny Dang,David W. White,Stefan Größ,Bryson D. Bennett,Mark Bittinger,Edward M. Driggers,Valeria R. Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin M. Marks,Robert M. Prins,Patrick S. Ward,Katharine Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Shinsan M. Su	3067

About Katharine Yen

Katharine Yen is a scholar working on Hematology, Genetics and Cancer Research, having authored 38 papers that have together received 5.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (19 papers), Cancer, Hypoxia, and Metabolism (16 papers) and Glioma Diagnosis and Treatment (13 papers). The work is most often cited by research in Genetics (2.1k citations), Cancer Research (2.8k citations) and Hematology (1.2k citations). Katharine Yen has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Lenny Dang, Shinsan M. Su, Valeria R. Fantin, Shengfang Jin, Stefan Größ, Craig B. Thompson, Patrick S. Ward, Matthew G. Vander Heiden, Marie C. Keenan and Joshua D. Rabinowitz. Their work appears in journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact